Chen XiaoHong1,2,3,4,5, Shen Bo1,2,3,4,5, Xiang FangFang1,2,3,4,5, Guo Man1,2,3,4,5, Zou JianZhou1,2,3,4,5, Liu ZhongHua1,2,3,4,5, Lv WenLv1,2,3,4,5, Cao XueSen1,2,3,4,5, Ding XiaoQiang6,7,8,9,10,11, Zhang Boheng12,13. 1. Shanghai Institute of Kidney and Dialysis, Shanghai, People's Republic of China. 2. Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, People's Republic of China. 3. Hemodialysis Quality Control Center of Shanghai, Shanghai, People's Republic of China. 4. Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. 5. Shanghai Medical Center of Kidney, Shanghai, People's Republic of China. 6. Shanghai Institute of Kidney and Dialysis, Shanghai, People's Republic of China. shen_dingxiaoqiang@163.com. 7. Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, People's Republic of China. shen_dingxiaoqiang@163.com. 8. Hemodialysis Quality Control Center of Shanghai, Shanghai, People's Republic of China. shen_dingxiaoqiang@163.com. 9. Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. shen_dingxiaoqiang@163.com. 10. Shanghai Medical Center of Kidney, Shanghai, People's Republic of China. shen_dingxiaoqiang@163.com. 11. Blood Purification Center, Zhongshan Hospital of Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China. shen_dingxiaoqiang@163.com. 12. Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. 13. Center for Evidence Based Medicine, Fudan University, Shanghai, People's Republic of China.
Abstract
BACKGROUND: Patients on chronic hemodialysis (HD) have an increased incidence of malignancy due to decreased immunity. Soluble interleukin-2 receptor (sIL-2R), as an immunomodulator, seemed to have an effect in the process of malignancy. In this study, we aimed to evaluate the clinical significance of increased sIL-2R in the course of malignancy among HD patients. METHODS: Patients who undergoing chronic hemodialysis were followed for 24 months. Risk factors for malignancy events and malignancy-related mortality during the 2-year follow-up period were investigated among various clinicopathological variables. RESULTS: Of the 363 patients included in this research, 47 patients (12.95%) had a prior history of treated malignancy. During the 2-year follow-up period, malignancy events were detected in 15 (4.12%) patients. Sixty-seven patients died during the study period, of which nine patients (13.43%) were died of malignancy. Malignancy events reduced 2-year mortality significantly (log-rank = 23.02, P < 0.0001). Both high sIL-2R levels ( ≥ 2-fold upper limit of the normal value) (OR 6.6, P = 0.006) and a prior history of treated malignancy (OR 4.12, P = 0.018)were identified by multivariate logistic analysis as independent determinants for malignancy events. However, only the levels of sIL-2R (used as a continuous variable) had the significantly predictive effect on malignancy events and malignancy-related mortality in the following 2 years. CONCLUSIONS: Elevated sIL-2R levels was commonly seen in serum of HD patients. And this elevated level increased the risk of malignancy. Aside from its role as a biomarker, sIL-2R may also exert biological effects in the course of malignancy.
BACKGROUND:Patients on chronic hemodialysis (HD) have an increased incidence of malignancy due to decreased immunity. Soluble interleukin-2 receptor (sIL-2R), as an immunomodulator, seemed to have an effect in the process of malignancy. In this study, we aimed to evaluate the clinical significance of increased sIL-2R in the course of malignancy among HDpatients. METHODS:Patients who undergoing chronic hemodialysis were followed for 24 months. Risk factors for malignancy events and malignancy-related mortality during the 2-year follow-up period were investigated among various clinicopathological variables. RESULTS: Of the 363 patients included in this research, 47 patients (12.95%) had a prior history of treated malignancy. During the 2-year follow-up period, malignancy events were detected in 15 (4.12%) patients. Sixty-seven patients died during the study period, of which nine patients (13.43%) were died of malignancy. Malignancy events reduced 2-year mortality significantly (log-rank = 23.02, P < 0.0001). Both high sIL-2R levels ( ≥ 2-fold upper limit of the normal value) (OR 6.6, P = 0.006) and a prior history of treated malignancy (OR 4.12, P = 0.018)were identified by multivariate logistic analysis as independent determinants for malignancy events. However, only the levels of sIL-2R (used as a continuous variable) had the significantly predictive effect on malignancy events and malignancy-related mortality in the following 2 years. CONCLUSIONS: Elevated sIL-2R levels was commonly seen in serum of HDpatients. And this elevated level increased the risk of malignancy. Aside from its role as a biomarker, sIL-2R may also exert biological effects in the course of malignancy.
Authors: Andy Huang; Helen Quinn; Clare Glover; Don C Henderson; Timothy G Allen-Mersh Journal: Cancer Immunol Immunother Date: 2002-01-10 Impact factor: 6.968
Authors: H Kobayashi; Y Tagaya; E S Han; I S Kim; N Le; C H Paik; I Pastan; D L Nelson; T A Waldmann; J A Carrasquillo Journal: Cytokine Date: 1999-12 Impact factor: 3.861
Authors: P Maisonneuve; L Agodoa; R Gellert; J H Stewart; G Buccianti; A B Lowenfels; R A Wolfe; E Jones; A P Disney; D Briggs; M McCredie; P Boyle Journal: Lancet Date: 1999-07-10 Impact factor: 79.321